Amphastar Pharmaceuticals, Inc. (AMPH)
NASDAQ: AMPH · Real-Time Price · USD
20.93
+0.02 (0.07%)
Aug 17, 2026, 12:26 PM EDT - Market open
Amphastar Pharmaceuticals Financials Overview
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Revenue Revenue Growth | 730.02 | 719.89 | 731.97 | 644.4 | 498.99 | 437.77 |
Revenue Growth | 1.02% | -1.65% | 13.59% | 29.14% | 13.98% | 25.13% |
Gross Profit Gross Profit Growth | 348.11 | 356.06 | 373.86 | 351.12 | 248.86 | 199.74 |
Operating Income Operating Income Growth | 137.39 | 163.5 | 205.42 | 196.99 | 107.5 | 71.69 |
Net Income Net Income Growth | 78.55 | 98.09 | 159.52 | 137.55 | 91.39 | 62.12 |
Earnings Per Share EPS Growth | 1.69 | 2.03 | 3.06 | 2.60 | 1.74 | 1.25 |
EPS Growth | -37.04% | -33.66% | 17.69% | 49.43% | 39.20% | 4090.97% |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
United States United States Growth | 683.21 | 681.42 | 707.68 | 635.19 | 486.83 | 419.87 |
China China Growth | 9.85 | 3.18 | 4.34 | 4.51 | 4.7 | 6.02 |
France France Growth | 36.96 | 35.28 | 19.95 | 4.7 | 7.46 | 11.88 |
Total Total Growth | 730.02 | 719.89 | 731.97 | 644.4 | 498.99 | 437.77 |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Investments Cash & Investments Growth | 290.12 | 282.81 | 221.65 | 256.81 | 175.76 | 136.67 |
Total Debt Total Debt Growth | 688.32 | 656 | 650.55 | 623.64 | 102.58 | 104.66 |
Net Cash (Debt) Net Cash Growth | -398.2 | -373.19 | -428.9 | -366.84 | 73.18 | 32.01 |
Net Cash Growth | - | - | - | - | 128.62% | -16.53% |
Net Cash Per Share Net Cash Per Share Growth | -8.59 | -7.74 | -8.24 | -6.92 | 1.40 | 0.64 |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Cash Flow Operating Cash Flow Growth | 184.61 | 156.12 | 213.39 | 183.5 | 89.18 | 97.99 |
Capital Expenditures CapEx Growth | -31.72 | -34.88 | -41.04 | -38.17 | -24.03 | -27.46 |
Free Cash Flow Free Cash Flow Growth | 152.89 | 121.23 | 172.35 | 145.34 | 65.15 | 70.54 |
Free Cash Flow Growth | 36.28% | -29.66% | 18.58% | 123.09% | -7.64% | 201.30% |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Gross Margin | 47.69% | 49.46% | 51.08% | 54.49% | 49.87% | 45.63% |
Operating Margin | 18.82% | 22.71% | 28.06% | 30.57% | 21.54% | 16.38% |
Pretax Margin | 13.98% | 17.17% | 25.85% | 26.28% | 23.02% | 19.17% |
Profit Margin | 10.76% | 13.63% | 21.79% | 21.34% | 18.31% | 14.19% |
FCF Margin | 20.94% | 16.84% | 23.54% | 22.55% | 13.06% | 16.11% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Aug '26 Aug 17, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 12.53 | 12.55 | 11.19 | 21.54 | 14.82 | 17.94 |
Forward PE | 7.01 | 7.78 | 9.42 | 20.77 | 16.29 | 16.96 |
P/FCF Ratio | 5.82 | 10.15 | 10.36 | 20.39 | 20.79 | 15.80 |
PS Ratio | 1.22 | 1.71 | 2.44 | 4.60 | 2.71 | 2.55 |